Elon Musk’s Neuralink startup has received approval from an independent review board for the first-in-human clinical trial of its brain implant chip. The company seeks volunteers among patients with paralysis due to cervical spinal cord injury or amyotrophic lateral sclerosis.
The purpose of the study is to evaluate the safety of the implant (N1) and the surgical robot that will perform the operation (R1), as well as the initial functionality of the brain-computer interface (BCI), which allows people with paralysis to control external devices with the power of thought.
- In May, the U.S. Food and Drug Administration allowed Neuralink to test brain chips in humans.
- In August, the company raised $280 million in a D round investment. Prior to this round, the brain chip developer was valued at $5 billion.
Author:
Karina Pardaeva
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
